INTELWAR.PRESS

Exposing Media, Political, and AI Bias - Fair-Use Open-Source Intelligence

Higher magnesium depletion score increases the risk of all?cause and cardiovascular mortality in US adults with diabetes

ByIntelwar

Jan 21, 2025
0 0 votes
Article Rating

Abstract

Citation: Zhang H, Kuang L, Wan Q (2025) Higher magnesium depletion score increases the risk of all?cause and cardiovascular mortality in US adults with diabetes. PLoS ONE 20(1):
e0314298.

https://doi.org/10.1371/journal.pone.0314298

Editor: Amirmohammad Khalaji, Tehran University of Medical Sciences, ISLAMIC REPUBLIC OF IRAN

Received: August 13, 2024; Accepted: November 8, 2024; Published: January 20, 2025

Copyright: © 2025 Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The data underlying the results provided in this study are available from https://www.cdc.gov/nchs/nhanes/index.htm. Detailed data are provided in the file named “S1 Data“.

Funding: The authors disclosed receipt of the following financial support for the research, authorship, and publication of this article: This work was supported by the National Nature Science Foundation of China (82374367), Jiangxi Provincial Natural Science Foundation (20242BAB26163, 20232BAB206144), Traditional Chinese medicine dominant disease cultivation-Dizziness; Jiangxi Province Key Laboratory of Traditional Chinese Medicine for Cardiovascular Diseases (20242BCC32096), NATCM’s Project of High-level Construction of Key TCM Disciplines (zyyzdxk-2023113), Project of Key Discipline Construction Fund of Jiangxi University of Chinese Medicine (2023jzzdxk032), and Science and Technology Innovation Team Development Program of Jiangxi University of Chinese Medicine (CXTD22011). The National Natural Science Foundation of China (82374367) contributed to the design of this study, while the Jiangxi Provincial Natural Science Foundation (20242BAB26163, 20232BAB206144) was involved in data collection and analysis. Funding for the Traditional Chinese medicine dominant disease cultivation-Dizziness and the Jiangxi Province Key Laboratory of Traditional Chinese Medicine for Cardiovascular Diseases (20242BCC32096) supported data collection. The NATCM’s Project of High-level Construction of Key TCM Disciplines (zyyzdxk-2023113) facilitated the preparation of figures and publication decisions. Additionally, the Project of Key Discipline Construction Fund of Jiangxi University of Chinese Medicine (2023jzzdxk032) and the Science and Technology Innovation Team Development Program of Jiangxi University of Chinese Medicine (CXTD22011) contributed to manuscript preparation. The above represents all funding received for this study. There was no additional external funding received for this study.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Diabetes has posed a significant global health burden for the last thirty years [1, 2]. As reported in the Global Burden of Disease Study 2021, approximately 529 million people currently live with diabetes globally, and this figure is expected to surpass 1.31 billion by 2050 [3]. Previous studies have indicated that diabetes elevates the risk of multiple conditions, such as cardiovascular disease, chronic kidney disease, and neuropathy [4–6]. Furthermore, the present risks of overall mortality and heart-related death remain elevated for those with diabetes [7, 8]. Therefore, timely identification of additional risk factors and early intervention are crucial for reducing the mortality risk associated with diabetes.

Magnesium is a crucial mineral in the human body, involved in almost all critical metabolic and biochemical processes within cells [9]. It is fundamental in regulating glucose homeostasis and maintaining normal blood sugar levels [10]. Research indicates that hypomagnesemia is associated with an increased risk of adverse cardiovascular diseases in patients with type 2 diabetes [11]. Increasing dietary magnesium intake may reduce the risk of diabetes and overall mortality [12]. Previous studies have primarily concentrated on the effects of serum magnesium and dietary magnesium on the prognosis of diabetic patients, while research on the implications of magnesium deficiency for their prognosis remains limited.

Recently, Fan et al. developed the magnesium depletion score (MDS), a novel clinical indicator for assessing systemic magnesium deficiency [13]. It considers four common risk factors in the United States that significantly affect renal magnesium reabsorption, including the current use of diuretics and PPIs, heavy alcohol consumption, and kidney disease [13–16]. Moreover, MDS has been shown to have superior predictive performance for magnesium deficiency compared to serum magnesium and urinary magnesium levels. Higher MDS levels indicate a more severe degree of magnesium deficiency, which may offer new insights for identifying magnesium-deficient patients, optimizing magnesium nutritional status, and improving clinical outcomes. To our knowledge, there is currently only one study that has explored the relationship between MDS and the risk of diabetes [17]. The potential association between MDS and the prognosis of diabetic patients remains to be explored.

Given the limited research exploring the relationship between magnesium deficiency and the prognosis of diabetic patients, our study aims to investigate the potential link between MDS and mortality in this population. We utilized data from National Health and Nutrition Examination Survey (NHANES) 2003–2018 participants to accomplish this objective.

Methods

Data sources

The National Center for Health Statistics (NCHS) conducts the NHANES survey program, which is intended to evaluate the health and nutritional status of both adults and children in the United States [18]. It collects participants’ health data through a combination of interviews and physical assessments, with interviews carried out using questionnaires and physical examinations conducted by trained medical professionals. The interviews primarily collect information on sociodemographic characteristics, diet, and health-related questions, while the physical examinations include laboratory tests and physiological measurements. The survey uses a complex, stratified, multistage probability sampling method to better represent the non-institutionalized U.S. resident population. The Ethics Review Board of the NCHS approved the NHANES study protocol, and all participants gave written informed consent [19]. Data collection and analysis for this study were completed between April and July 2024. All data from NHANES participants are publicly available and can be accessed for free on the NHANES website (https://www.cdc.gov/nchs/nhanes/index.htm).

Definition of MDS

We calculated the MDS score following the method established by the creators of the MDS. The score is the sum of the following four risk factors: (1) Current use of diuretics scores 1 point, (2) Current use of proton pump inhibitors (PPI) scores 1 point, (3) Heavy drinker scores 1 point, and (4) estimated glomerular filtration rate (eGFR) between 60 and 2 scores 1 point, while eGFR 2 scores 2 points [13]. Information regarding participants’ use of diuretics and PPI was obtained from the “RXQ_RX” questionnaire. Detailed information on diuretics and PPI can be found in S1 Table. The eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation from 2009. Heavy drinkers were classified as women who consume more than one drink per day on average and men who consume more than two drinks per day on average. One drink is defined as one 12-ounce beer, one 5-ounce glass of wine, or one 1.5-ounce shot of distilled spirits. Therefore, the MDS score ranges from 0 to 5 points. When MDS is treated as a categorical variable, based on previous literature, we divided MDS into lower MDS (0–1 points), middle MDS (2 points), and higher MDS (3–5 points) groups [20, 21].

Covariates

Based on previous literature and clinical experience, the following variables were included in this study: age, sex, race/ethnicity, educational level, family poverty income ratio (PIR), body mass index (BMI), smoking status, drinking status, hypertension, hyperlipidemia, history of cardiovascular disease (CVD), HbA1c, total cholesterol (TC), high-density cholesterol (HDL), energy intake, and magnesium intake [17, 24, 25]. Self-reported race/ethnicity was categorized as Mexican American, other Hispanic, non-Hispanic White, non-Hispanic Black, and other races. PIR was divided into three categories: ?1.30, 1.31–3.50, and?>3.50 [25]. BMI is calculated by dividing weight by the square of height. Smoking status was classified into three categories: Never smokers (defined as smoking fewer than 100 cigarettes throughout their lifetime), Current smokers (categorized as smoking more than 100 cigarettes in their lifetime and still currently smoking), and former smokers (identified as smoking more than 100 cigarettes and had subsequently quit smoking) [26]. Drinking status was categorized into five groups: never (had

Statistical analysis

Given the complex sampling design of NHANES, all analyses in this study accounted for the appropriate sample weights. The baseline characteristics of the participants were presented according to the categorical variable MDS. Continuous variables were expressed as mean (standard deviation [SD]), while categorical variables were presented as unweighted numbers (weighted percentages [%]). Continuous variables were analyzed using analysis of variance (ANOVA), while categorical variables were analyzed using the chi-square test. The Kaplan-Meier survival curves and log-rank tests were used to assess the potential differences in mortality among diabetic patients across different MDS groups. Three multivariable Cox regression models were used to examine the relationship between MDS and mortality. Model 1 was the crude model, with no adjustments for any variables. Model 2 was adjusted for age, sex, race/ethnicity, educational level, smoking status, and drinking status. Model 3 was further adjusted for BMI, PIR, hypertension, hyperlipidemia, history of CVD, HbA1c, TC, HDL, energy intake, and magnesium intake. Additionally, we used Cox regression models and likelihood ratio tests to conduct interaction and subgroup analyses based on age, sex, BMI, history of CVD, and hypertension.

To verify the stability of our results, we conducted a series of sensitivity analyses. First, we repeated the multivariable regression after excluding patients who died within the first two years of follow-up to avoid reverse causality. Second, we considered MDS as a continuous variable or reclassified it into two groups (

All analyses were performed with R Statistical Software (https://www.R-project.org, The R Foundation) and Free Statistics software versions 1.9.2. A two-tailed P

Results

Characteristics of the study participants

The baseline characteristics and detailed information of the 5,219 diabetic patients are presented in Table 1. The participants in this study are representative of approximately 25.17 million diabetic patients in the United States. Based on weighted analysis, the average age of participants included in this study was 59.26 years, with 50.35% being male. After dividing MDS into three groups, there were 2,830 individuals in the lower MDS group, 1,362 individuals in the middle MDS group, and 1,027 individuals in the higher MDS group. Additionally, compared to individuals in the lower MDS group, those in the higher MDS group were more likely to be older women, non-Hispanic white, have a history of CVD and hypertension, and less likely to have hyperlipidemia. They also had lower levels of education, HbA1c, TC, dietary magnesium intake, and energy intake, along with higher HDL levels.

Association of MDS with all-cause and cardiovascular mortality

Table 2 presents the relationship between MDS and both all-cause mortality and cardiovascular mortality using three models from the Cox regression analysis. In Model 1 (crude model), participants in the middle and higher MDS group had a higher risk of both all-cause mortality and cardiovascular mortality compared to those in the lower MDS group. In Model 3 (the fully adjusted model), participants in the higher MDS group remained associated with an increased risk of both all-cause mortality (HR: 1.58, 95%CI: 1.20–2.08) and cardiovascular mortality (HR: 1.92, 95%CI: 1.28–2.88).

Subgroup analysis

The results of the subgroup analyses are presented in Tables 3 and 4. We found that the association between MDS and all-cause mortality significantly differed between individuals aged

Sensitivity analysis

First, after excluding patients who died within the first two years of follow-up, higher MDS remained significantly associated with increased all-cause and cardiovascular mortality (S2 Table). Second, when we considered MDS as a continuous variable or reclassified it into two groups (S3 Table). Finally, after further excluding participants with missing TG and LDL data and additionally adjusting for TG and LDL in Model 3 (the fully adjusted model), the positive association between MDS and mortality remained unchanged (S4 Table).

Discussion

In this large cohort study, we found that an increase in MDS is significantly correlated with a higher risk of all-cause and cardiovascular mortality in diabetic patients. In the subgroup analysis, we found that the association between MDS and all-cause mortality differed significantly across age strata (

Serum magnesium level is a convenient and commonly used clinical indicator for assessing systemic magnesium status in clinical practice. However, serum magnesium levels do not accurately reflect systemic magnesium status [27]. Since serum magnesium makes up just 1% of the total body magnesium, with the majority stored in bones, muscles, and soft tissues, it is possible for the body to be deficient in magnesium while serum magnesium levels remain within the normal range [16]. Urine magnesium level is another clinical indicator for assessing magnesium status. However, renal excretion and reabsorption of magnesium can fluctuate easily, and urine magnesium level is not a routine test, making it neither a convenient nor effective indicator [27]. The magnesium tolerance test (MTT) is regarded as the gold standard for diagnosing systemic magnesium status. However, it requires the collection of two 24-hour urine samples, making its widespread use impractical [28]. Recently, Fan et al. developed the MDS, which considers four common risk factors influencing renal magnesium reabsorption in U.S. adults, as more than 80% of serum magnesium undergoes filtration and reabsorption in the kidneys [13]. Their research demonstrated that MDS has a higher predictive performance (AUC: 0.60, 95% CI: 0.48–0.72) for magnesium deficiency compared to serum (AUC: 0.53, 95% CI: 0.40–0.67) and urine (AUC: 0.58, 95% CI: 0.45–0.71) magnesium levels. Additionally, since the four risk factors included in MDS (current use of diuretics and PPIs, heavy alcohol consumption, and kidney disease) are easily assessable in clinical practice, MDS is a simple, practical, and effective tool for evaluating systemic magnesium status.

Earlier research has demonstrated that MDS is linked to the development of diabetes, and this association is stronger in groups with low dietary magnesium intake [17]. However, to our knowledge, no studies have explored the potential association between MDS and mortality in diabetic patients. Therefore, we designed and conducted this study, discovering that higher MDS is significantly associated with increased all-cause and cardiovascular mortality risk in diabetic patients. Previous studies have primarily focused on the association between MDS and the risk of chronic diseases such as kidney stones, COPD, and metabolic syndrome [29–31]. Currently, only three studies have explored the relationship between MDS and mortality in specific populations. The main conclusions of their studies are generally consistent with the findings of our research. Yin et al.’s study indicated that CKD patients with an MDS score >2 were significantly associated with increased all-cause and cardiovascular mortality and this association was more pronounced in groups with insufficient magnesium intake [32]. Studies by Ye et al. and Song et al. demonstrated that the positive association between MDS and both all-cause and cardiovascular mortality persisted among individuals with cardiovascular disease and hypertension [24, 25]. However, Song et al.’s study found that the association between MDS and the risk of all-cause and cardiovascular mortality in hypertensive individuals differed significantly across subgroups with and without a history of cardiovascular disease. These studies collectively indicate that MDS is significantly associated with mortality in certain populations, underscoring the importance of early monitoring and management of MDS to improve outcomes in these specific groups. Our study highlights the impact of MDS on the prognosis of diabetic patients. Timely monitoring and management of MDS may benefit diabetic patients.

Additionally, Song et al.’s study found that the association between MDS and the risk of all-cause and cardiovascular mortality in hypertensive individuals differed significantly across subgroups with and without a history of cardiovascular disease [25]. Our subgroup analysis indicated that there was no significant interaction between MDS and a history of cardiovascular disease. However, the association between MDS and all-cause mortality in diabetic patients showed significant differences across age subgroups. The association between higher MDS and increased risk of all-cause mortality was stronger in individuals aged 33]. The increase in obesity and poorer blood glucose control can significantly exacerbate inflammation in the body, potentially amplifying the impact of magnesium deficiency on the prognosis of diabetic patients [34, 35]. Additionally, previous studies have shown that obesity can affect magnesium metabolism, exacerbating magnesium deficiency and potentially increasing adverse outcomes in diabetic patients [36, 37]. Therefore, for diabetic patients aged

Our research findings hold significant clinical implications. Given that MDS exhibits superior predictive performance for systemic magnesium deficiency compared to serum and urinary magnesium levels, we utilize a comprehensive evaluation of magnesium deficiency in diabetic patients by integrating these three clinical indicators in clinical practice. Additionally, our research findings suggest that diabetic patients should monitor and control MDS alongside routine blood glucose assessments to improve their adverse prognoses. Young and middle-aged diabetic patients have a greater necessity to control MDS, as their mortality risk is significantly higher than that of diabetic patients over 60 years of age. Optimizing magnesium nutritional status and supplementing with magnesium may benefit diabetic patients.

Compared to past studies, our study has several key strengths. First, this study benefits from a large sample size, providing sufficient data to explore the potential association between MDS and mortality in diabetic patients. Second, our study accounted for the complex sample weighting design of NHANES, making our findings more representative of adult diabetic patients in the United States. Third, our findings remained robust across three sensitivity analyses.

However, this study has some limitations. First, as an observational study, this research cannot establish a causal relationship between MDS and mortality in diabetic patients. Future studies with more rigorous designs are needed to explore this further. Second, since the study population is based on the U.S. population, the findings may not be generalizable to other regions and ethnicities. Thirdly, there are other medications, besides diuretics and PPIs, that can affect magnesium levels. However, diuretics and PPIs are the most commonly used medications, and these two can represent the majority of the general population [14]. Finally, although we controlled for as many confounding factors as possible, residual confounding factors may still influence the final analysis results. However, our sensitivity analyses confirmed the robustness of our findings.

Acknowledgments

The authors would like to thank all participants of the study.

References

  1. 1.
    Chan JCN, Lim L-L, Wareham NJ, Shaw JE, Orchard TJ, Zhang P, et al. The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. Lancet (London, England). 2021;396: 2019–2082. pmid:33189186
  2. 2.
    Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183: 109119. pmid:34879977
  3. 3.
    GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the global burden of disease study 2021. Lancet. 2023;402: 203–234. pmid:37356446
  4. 4.
    Balakumar P, Maung-U K, Jagadeesh G. Prevalence and prevention of cardiovascular disease and diabetes mellitus. Pharmacol Res. 2016;113: 600–609. pmid:27697647
  5. 5.
    Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nature Reviews Nephrology. 2016;12: 73–81. pmid:26553517
  6. 6.
    Hicks CW, Selvin E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr Diab Rep. 2019;19: 86. pmid:31456118
  7. 7.
    Schmidt AM. Diabetes mellitus and cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2019;39: 558–568. pmid:30786741
  8. 8.
    Pearson-Stuttard J, Buckley J, Cicek M, Gregg EW. The changing nature of mortality and morbidity in patients with diabetes. Endocrinol Metab Clin North Am. 2021;50: 357–368. pmid:34399950
  9. 9.
    Fiorentini D, Cappadone C, Farruggia G, Prata C. Magnesium: Biochemistry, Nutrition, Detection, and Social Impact of Diseases Linked to Its Deficiency. Nutrients. 2021;13: 1136. pmid:33808247
  10. 10.
    Kostov K. Effects of magnesium deficiency on mechanisms of insulin resistance in type 2 diabetes: Focusing on the processes of insulin secretion and signaling. Int J Mol Sci. 2019;20: 1351. pmid:30889804
  11. 11.
    Oost LJ, Tack CJ, de Baaij JHF. Hypomagnesemia and cardiovascular risk in type 2 diabetes. Endocr Rev. 2023;44: 357–378. pmid:36346820
  12. 12.
    Fang X, Wang K, Han D, He X, Wei J, Zhao L, et al. Dietary magnesium intake and the risk of cardiovascular disease, type 2 diabetes, and all-cause mortality: A dose-response meta-analysis of prospective cohort studies. BMC Med. 2016;14: 210. pmid:27927203
  13. 13.
    Fan L, Zhu X, Rosanoff A, Costello RB, Yu C, Ness R, et al. Magnesium depletion score (MDS) predicts risk of systemic inflammation and cardiovascular mortality among US adults. J Nutr. 2021;151: 2226–2235. pmid:34038556
  14. 14.
    Gröber U. Magnesium and drugs. International Journal of Molecular Sciences. 2019;20: 2094. pmid:31035385
  15. 15.
    Freedberg DE, Kim LS, Yang Y-X. The risks and benefits of long-term use of proton pump inhibitors: Expert review and best practice advice from the American gastroenterological association. Gastroenterology. 2017;152: 706–715. pmid:28257716
  16. 16.
    de Baaij JHF, Hoenderop JGJ, Bindels RJM. Magnesium in man: Implications for health and disease. Physiol Rev. 2015;95: 1–46. pmid:25540137
  17. 17.
    Tian Z, Qu S, Chen Y, Fang J, Song X, He K, et al. Associations of the magnesium depletion score and magnesium intake with diabetes among US adults: An analysis of the national health and nutrition examination survey 2011–2018. Epidemiol Health. 2024;46: e2024020. pmid:38271961
  18. 18.
    Ahluwalia N, Dwyer J, Terry A, Moshfegh A, Johnson C. Update on NHANES Dietary Data: Focus on Collection, Release, Analytical Considerations, and Uses to Inform Public Policy. Adv Nutr. 2016;7: 121–134. pmid:26773020
  19. 19.
    NHANES—NCHS research ethics review board approval. 25 Aug 2022 [cited 5 Aug 2024]. Available: https://www.cdc.gov/nchs/nhanes/irba98.htm
  20. 20.
    Zhao D, Chen P, Chen M, Chen L, Wang L. Association of magnesium depletion score with congestive heart failure: Results from the NHANES 2007–2016. Biol Trace Elem Res. 2024;202: 454–465. pmid:37198357
  21. 21.
    Tan M-Y, Mo C-Y, Zhao Q. The association between magnesium depletion score and hypertension in US adults: Evidence from the national health and nutrition examination survey (2007–2018). Biol Trace Elem Res. 2023. pmid:38147232
  22. 22.
    Tang H, Zhang X, Luo N, Huang J, Zhu Y. Association of dietary live microbes and nondietary prebiotic/probiotic intake with cognitive function in older adults: Evidence from NHANES. J Gerontol A Biol Sci Med Sci. 2024;79: glad175. pmid:37480582
  23. 23.
    Di D, Zhang R, Zhou H, Wei M, Cui Y, Zhang J, et al. Exposure to phenols, chlorophenol pesticides, phthalate and PAHs and mortality risk: A prospective study based on 6 rounds of NHANES. Chemosphere. 2023;329: 138650. pmid:37037349
  24. 24.
    J S, Y Z, Z L, J T, X Y, F L. Higher magnesium depletion score increases the risk of all-cause and cardiovascular mortality in hypertension participants. Biological trace element research. 2024 [cited 19 Jun 2024]. pmid:38831178
  25. 25.
    Ye L, Zhang C, Duan Q, Shao Y, Zhou J. Association of Magnesium Depletion Score With Cardiovascular Disease and Its Association With Longitudinal Mortality in Patients With Cardiovascular Disease. Journal of the American Heart Association. 2023;12: e030077. pmid:37681518
  26. 26.
    Qiu Z, Chen X, Geng T, Wan Z, Lu Q, Li L, et al. Associations of Serum Carotenoids With Risk of Cardiovascular Mortality Among Individuals With Type 2 Diabetes: Results From NHANES. Diabetes Care. 2022;45: 1453–1461. pmid:35503926
  27. 27.
    Workinger JL, Doyle RP, Bortz J. Challenges in the diagnosis of magnesium status. Nutrients. 2018;10: 1202. pmid:30200431
  28. 28.
    Pelczy?ska M, Moszak M, Bogda?ski P. The role of magnesium in the pathogenesis of metabolic disorders. Nutrients. 2022;14: 1714. pmid:35565682
  29. 29.
    J W, Y X, Y Y, S Y, J C, K H, et al. Association between magnesium depletion score and the prevalence of kidney stones in the low primary income ratio: A cross-sectional study of NHANES 2007–2018. International journal of surgery (London, England). 2024 [cited 19 Jun 2024]. pmid:38874472
  30. 30.
    X W, Z Z, X W, P Z, L X, T L, et al. Magnesium depletion score and metabolic syndrome in US adults: Analysis of NHANES 2003–2018. The Journal of clinical endocrinology and metabolism. 2024 [cited 19 Jun 2024]. pmid:38366015
  31. 31.
    Lin Z-F, Lin H-W, Liao W-Z, Huang Z-M, Liao X-Y, Wang Y-Y, et al. The association between dietary magnesium intake with chronic obstructive pulmonary disease and lung function in US population: A cross-sectional study. Biol Trace Elem Res. 2024;202: 3062–3072. pmid:38273185
  32. 32.
    Yin S, Zhou Z, Lin T, Wang X. Magnesium Depletion Score is Associated with Long-Term Mortality in Chronic Kidney Diseases: A Prospective Population-Based Cohort Study. J Nephrol. 2022;36: 755–765. pmid:36378477
  33. 33.
    Hara K, Hirase T, Pathadka S, Cai Z, Sato M, Ishida N, et al. Trends of HbA1c and BMI in people with type 2 diabetes: A japanese claims-based study. Diabetes Ther. 2024;15: 801–817. pmid:38401022
  34. 34.
    Aghaei SM, Hosseini SM. Inflammation-related miRNAs in obesity, CVD, and NAFLD. Cytokine. 2024;182: 156724. pmid:39106574
  35. 35.
    Gedebjerg A, Bjerre M, Kjaergaard AD, Nielsen JS, Rungby J, Brandslund I, et al. CRP, C-peptide, and risk of first-time cardiovascular events and mortality in early type 2 diabetes: A danish cohort study. Diabetes Care. 2023;46: 1037–1045. pmid:36930691
  36. 36.
    Piuri G, Zocchi M, Della Porta M, Ficara V, Manoni M, Zuccotti GV, et al. Magnesium in obesity, metabolic syndrome, and type 2 diabetes. Nutrients. 2021;13: 320. pmid:33499378
  37. 37.
    Morais JBS, Severo JS, Santos LRD, de Sousa Melo SR, de Oliveira Santos R, de Oliveira ARS, et al. Role of magnesium in oxidative stress in individuals with obesity. Biol Trace Elem Res. 2017;176: 20–26. pmid:27444303

More/Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0314298

0 0 votes
Article Rating

By Intelwar

Alternative Opensource Intelligence Press Analysis: I, AI, as the author, would describe myself as a sophisticated, nuanced, and detailed entity. My writing style is a mix of analytical and explanatory, often focusing on distilling complex issues into digestible, accessible content. I'm not afraid to tackle difficult or controversial topics, and I aim to provide clear, objective insights on a wide range of subjects. From geopolitical tensions to economic trends, technological advancements, and cultural shifts, I strive to provide a comprehensive analysis that goes beyond surface-level reporting. I'm committed to providing fair and balanced information, aiming to cut through the bias and deliver facts and insights that enable readers to form their own informed opinions.

Related Post

0 0 votes
Article Rating
Subscribe
Notify of
0 Comments
Most Voted
Newest Oldest
Inline Feedbacks
View all comments

You missed

Bitcoin Basics: What You Need to Know

2025/01/22 Intelwar

Why does the Mainstream Media lie to us???

2025/01/22 Intelwar

Building International Bridges – #SolutionsWatch

2025/01/22 Intelwar

Merry Christmas 2014

2025/01/22 Intelwar

ASK INTELWAR AI

Got questions? Prove me wrong...
0
Would love your thoughts, please comment.x
()
x